10
Orphan Designations
0
FDA Approvals
27
Rare Diseases
0
News Articles
| Disease | Drug(s) | Designation | Approved |
|---|---|---|---|
| Alstrom syndrome | tremelimumab | Orphan Designation | - |
| Finnish type amyloidosis | tremelimumabetaracizumab | Orphan Designation | - |
| Norum disease | recombinant human lecithin:cholesterol acyltransferase (rhLCAT) | Orphan Designation | - |
| T-cell non-Hodgkin lymphoma | siplizumab | Orphan Designation | - |
| Toriello-Lacassie-Droste syndrome | Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine | Orphan Designation | - |
| anal canal carcinoma in situ | etaracizumab | Orphan Designation | - |
| angioimmunoblastic T-cell lymphoma | siplizumab | Orphan Designation | - |
| familial caudal dysgenesis | recombinant human lecithin:cholesterol acyltransferase (rhLCAT) | Orphan Designation | - |
| familial ovarian cancer | recombinant human lecithin:cholesterol acyltransferase (rhLCAT) | Orphan Designation | - |
| grade III prostatic intraepithelial neoplasia | etaracizumab | Orphan Designation | - |
| graft versus host disease | Humanized anti-CD2 monoclonal antibody | Orphan Designation | - |
| hepatosplenic T-cell lymphoma | siplizumab | Orphan Designation | - |
| idiopathic pulmonary fibrosis | tralokinumab | Orphan Designation | - |
| lysinuric protein intolerance | tremelimumab | Orphan Designation | - |
| malignant mesothelioma | tremelimumab | Orphan Designation | - |
| nut midline carcinoma | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| ovarian cancer | Anti-EphA1 monoclonal antibody conjugated to mcMMAF | Orphan Designation | - |
| penis carcinoma in situ | etaracizumab | Orphan Designation | - |
| respiratory failure | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| respiratory or thoracic malformation | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| respiratory syncytial virus bronchiolitis | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| respiratory syncytial virus infectious disease | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| respiratory system benign neoplasm | Respiratory Syncytial Virus Immune Globulin (human) | Orphan Designation | - |
| squamous carcinoma in situ | etaracizumab | Orphan Designation | - |
| transient bullous dermolysis of the newborn | Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine | Orphan Designation | - |
| transient erythroblastopenia of childhood | Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine | Orphan Designation | - |
| uterine cervix carcinoma in situ | etaracizumab | Orphan Designation | - |